PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fruquintinib→

Fruquintinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1194506-26-7
Molecular formula
C21H19N3O5
Molecular weight
393.4 g/mol
Drug class
Selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorantineoplastic
Mechanism of action
Inhibits VEGFR1, VEGFR2 and VEGFR3 kinase activity, suppressing angiogenesis and tumour-associated vascular signalling.
Indications / reported uses
  • Treatment of adults with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy and, if RAS wild-type, anti-EGFR therapy, under the applicable US product indication

Sources: US DailyMed — FRUZAQLA (fruquintinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fruquintinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fruquintinib Permitted Daily Exposure (PDE) report (the Fruquintinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fruquintinib Occupational Exposure Limit (OEL) report (the Fruquintinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.